MedPath

Ocumension (Hong Kong) Limited

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:6
Completed:0

Trial Phases

2 Phases

Phase 1:5
Phase 3:2

Drug Approvals

1

PPB:1

Drug Approvals

OCUSINGEN INTRAVITREAL IMPLANT 0.19MG

Approval Date
Dec 13, 2023
PPB

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 3
2 (28.6%)

Study of OT-101 in Treating Myopia

Phase 3
Active, not recruiting
Conditions
Myopia, Progressive
Interventions
Drug: OT-101 Ophthalmic Solution
Drug: Vehicle
First Posted Date
2021-02-25
Last Posted Date
2023-08-08
Lead Sponsor
Ocumension (Hong Kong) Limited
Target Recruit Count
678
Registration Number
NCT04770610
Locations
🇺🇸

Colorado Vision Institute, Colorado Springs, Colorado, United States

🇺🇸

Eye Center of Northern Colorado, PC, Fort Collins, Colorado, United States

🇺🇸

Family Focus, Gainesville, Florida, United States

and more 12 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.